MIGUEL ÁNGEL CALLEJA HERNÁNDEZ-rekin lankidetzan egindako argitalpenak (56)

2024

  1. Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study

    Journal of Clinical Medicine, Vol. 13, Núm. 4

2023

  1. Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 15

2021

  1. Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis

    Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47

  2. Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives

    Mutation Research - Reviews in Mutation Research, Vol. 788

  3. Impact of a risk-sharing agreement in rheumatoid arthritis in Spain

    Health Policy, Vol. 125, Núm. 3, pp. 335-340

  4. Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis

    Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726

  5. Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis

    Journal of Personalized Medicine, Vol. 11, Núm. 5

2020

  1. Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis

    Pathology Research and Practice, Vol. 216, Núm. 4

  2. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta

    Mutation Research - Reviews in Mutation Research, Vol. 785

2019

  1. Clinical pharmacy services: From cost-effectiveness analysis to a productivity indicators model

    European Journal of Hospital Pharmacy

  2. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

    Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177

2018

  1. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer

    Pathology Research and Practice, Vol. 214, Núm. 1, pp. 44-52

2017

  1. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

    Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58

  2. Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer

    Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444

  3. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer

    Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285

2016

  1. Liquid biopsy in early stage lung cancer

    Translational Lung Cancer Research, Vol. 5, Núm. 5, pp. 517-524

  2. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients

    Pharmacological Research, Vol. 111, pp. 877-884

  3. Resultados negativos asociados a la medicación en los pacientes con fibrilación auricular permanente atendidos en un servicio de urgencias hospitalario

    Emergencias, Vol. 28, Núm. 2, pp. 75-82

2015

  1. Differences in cancer drug assessment between Spain and the United Kingdom

    European Journal of Cancer, Vol. 51, Núm. 13, pp. 1843-1852

  2. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

    Pharmacological Research, Vol. 102, pp. 90-106